Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T22:31:43.474Z.
Calculation as of: 2026-10-06T22:31:43.474Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5ff4a69d5e0bd829addfa263bba904bf87580f902e4d2830b11cef9910c58a28
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Entera Bio Ltd.
Market Cap
$124.70M
Free Cash Flow Yield
N/A
| NAME | MARKET CAP | FREE CASH FLOW YIELD |
|---|---|---|
| Entera Bio Ltd. (ENTX) | $124.70M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $124.18M | N/A |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $122.66M | N/A |
| BGM Group Ltd. (BGM)vs › | $122.43M | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $127.29M | N/A |
| Pyxis Oncology, Inc. (PYXS)vs › | $127.98M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | N/A |
| Seer, Inc. (SEER)vs › | $120.41M | N/A |
| Cibus, Inc. (CBUS)vs › | $119.84M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.83M | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
